Abivax (ABVX) said Thursday that it reached 82% of target enrollment in a phase 3 trial evaluating obefazimod for the treatment of moderately to severely active ulcerative colitis.
Enrollment stood at 1,003 of 1,224 targeted participants and is expected to be completed in Q2, according to the biotechnology company.
The company's cash runway will extend beyond the trial readout and into Q4, Abivax said.
Price: 6.68, Change: -0.30, Percent Change: -4.30
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。